DEA Reclassifies Plant-Derived Marijuana Medicine To Schedule V

Generic 28 September 2018 | 0 Comments

Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The US Food and Drug Administration had previously approved the product in June for the explicit treatment of two rare forms […]

Tagged in , , ,